NasdaqGS:ELVNPharmaceuticals
22% Below Analyst Target, Is Enliven Therapeutics (ELVN) Fairly Valued Here
Enliven Therapeutics (ELVN) stock has drawn investor attention after recent trading, which left the company valued at about US$2.9b and its shares closing at US$49.12, alongside mixed annual revenue and net income growth figures.
See our latest analysis for Enliven Therapeutics.
At the current share price of US$49.12, Enliven Therapeutics has seen strong momentum, with a 1 month share price return of 15.49% and a year to date share price return of 216.09%, alongside a 1 year total shareholder...